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Do hyaluronic acid injections 
relieve OA knee pain?
Evidence-based answer
Yes, hyaluronic acid (HA) injections relieve 
pain more than placebo. The effect is 
small but similar to results from oral 
nonsteroidal anti-inflammatory drugs 
(nsAIDs) or steroid injection (strength of 
recommendation ([sOr]: B, conflicting 
meta-analyses). The various HA products 
all appear to be equally effective in 
reducing pain (sOr: B, randomized 
clinical trials [rCTs]). Data concerning 
the effect of HA on functional ability are 
conflicting.
z  Evidence summary
A 2005 meta-analysis evaluated the ef-
fectiveness of HA injections for osteo-
arthritis of the knee compared with 
saline placebo. Researchers identified 22 
studies of 8 HA products that used the 
common end point of pain with move-
ment.1 (TABLE 1 lists FDA-approved HA 
products available in the United States.2) 
A decrease in pain of 15% was deemed 
clinically meaningful. 
Compared with placebo, the mean 
difference in pain scores with HA prod-
ucts was −4% (95% confidence interval 
[CI], −9% to 1%) after 2 to 6 weeks; 
−4% (95% CI, −8% to −1%) after 10 
to 14 weeks; and −7% (95% CI, −12% 
to −2%) after 22 to 30 weeks. The au-
thors note that the small measured effect 
of HA was magnified by trials that didn’t 
report intention-to-treat results. The ef-
fect of HA was also larger in studies that 
didn’t conceal allocation. A weakness of 
the analysis was its inability to assess po-
tential differences between HA products. 
In this 2005 meta-analysis, HA injec-
tion didn’t improve knee function in any 
time interval.  But in a Cochrane meta-
analysis conducted the following year, 
HA was found to have positive results.3 
z  HA relieves pain  
about as much as NSAIDs 
The  comprehensive 2006 Cochrane  meta- 
analysis reviewed single- and double-
blinded RCTs that evaluated the effect of 
12 HA products on osteoarthritis of the 
knee.3 Studies compared HA products 
with placebo (40), intra-articular steroids 
(10), NSAIDs (6), physical therapy (3), 
exercise (2), and each other (15). Efficacy 
data for different products couldn’t be 
combined because the studies measured 
different sets of outcomes at different 
time points. 
Overall, the authors concluded that 
HA injections effectively reduced pain 
scores, with the largest benefit occurring 
within 5 to 13 weeks (TABLE 2). The au-
thors also noted that the reductions in 
pain with HA injections, although gen-
erally small, were comparable to oral 
NSAID therapy and intra-articular cor-
ticosteroids. The trials reported few ad-
verse events.
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Two RCTs show no difference 
in efficacy among HA products
The Cochrane review determined 
that not enough evidence existed to 
evaluate HA products against each 
other. Two subsequent RCTs com-
pared HA products and found no 
differences in efficacy. One study com-
pared Synvisc, Orthovisc, and Os-
tenil therapy in 660 patients over 6 
months.4 The other compared Synvisc 
with Euflexxa in 321 patients over 
3 months.5 Notably, 8% of patients in 
this study who used Synvisc developed 
an effusion, compared with 0.6% of 
patients who used Euflexxa (P=.0015). 
Recommendations
A 2007 report from the Agency for 
Healthcare Research and Quality 
(AHRQ) states that “viscosupplementa-
tion trials generally report positive effects 
on pain and function scores compared 
with placebo, but the evidence on clinical 
benefit is uncertain.”6 
The 2007 guidelines of the Institute 
for Clinical Systems Improvement note 
that synthetic hyaluronates “may be ef-
fective” in selected patients with mild 
to moderate degenerative joint disease 
(based on evidence of middle quality on 
a 3-tier grading system).7 
The American Academy of Ortho-
paedic Surgeons 2008 guideline on osteo-
arthritis of the knee indicates that, based 
on the AHRQ report,6 it cannot recom-
mend for or against the use of intra- 
articular hyaluronic acid for mild to mod-
erate symptomatic OA of the knee.8 n
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FDA-approved hyaluronic acid products
TRadE namE cOmpOsiTiOn
mOlEculaR 
wEighT 
(×106  dalTOns)
cOsT pER  
injEcTiOn* 
(3-5 dOsEs) sOuRcE
hyalgan sodium hyaluronate 0.5-0.7 $138 Avian
supartz sodium hyaluronate 0.6-1.2 $136 Avian
Euflexxa sodium hyaluronate 2.4-3.6 $133 Bacterial
Orthovisc Hyaluronin 1.0-2.9 $238 Avian
synvisc Hylan G-F 20 6.0 $230 Avian
*Prices from www.drugstore.com (accessed June 18, 2008); all other data from Waddell DD.2
table 1
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Data concerning 
the effect of HA on 
joint function are 
conflicting.
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How HA products affect pain measures 
pROducT cOmpaRaTOR OuTcOmE
aT 1-4 wEEks aT 5-13 wEEks
n
pERcEnT changE 
vs cOmpaRaTOR* 
(95% ci) n
pERcEnT changE 
vs cOmpaRaTOR* 
(95% ci)
ha/hyalin Placebo Pain on weight bearing 2542 −8 (−11 to −4) 2090 −13 (−18 to −8)
hyalgan Placebo Pain on weight bearing 1398 −6 (−11 to −1) 1095 −9 (−14 to −4)
synvisc Placebo Pain on weight bearing 481 −13 (−20 to −5) 155 −10 (−14 to −5)
suplasyn Placebo WOMAC pain 53 ns (Data not available)
durolane Placebo WOMAC pain  346 4 (0 to 7) 436 ns
Orthovisc Placebo WOMAC pain 110 −12 (−13 to −10) 69 −5 (−7 to −4)
ha/hyalin nsAID Pain after walking 333 ns (Data not available)
hyalgan nsAID Pain after 50-foot walk 279 ns 140 ns
synvisc nsAID Pain at rest (Data not available) 57 ns
suplasyn nsAID Pain after walking 54 ns (Data not available)
hyalgan Methylprednisolone spontaneous pain 170 ns 170 −8 (−13 to −3)
synvisc Triamcinolone WOMAC pain, walking (Data not available) 215 −10 (−17 to −3)
Orthovisc Methylprednisolone Pain, walking 55 ns 55 −18 (−29 to −8)
us medications supartz and euflexxa were not included in the Cochrane review. 
CI, confidence interval; HA, hyaluronic acid; ns, not statistically significant; nsAID, nonsteroidal anti-inflammatory drug; WOMAC, Western Ontario and 
MacMaster universities Osteoarthritis Index.
*negative values favor HA products.  
source: Bellamy n, et al. Cochrane Database Syst. Rev. 2006.3  
table 2
HA products  
apparently do not 
differ in efficacy, 
based on 2 RCTs.
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